Physician profile
David B Oliver
NPI 1679558399
$5,738.34
in general payments reported to CMS, 2019-2025
23 companies · $620 in 2025
The $620 reported for 2025 was more than what 82% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,063 · 2020: $378 · 2021: $613 · 2022: $876 · 2023: $466 · 2024: $721 · 2025: $620.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,808.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,807.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $1,425.42 | 2019-2025 | Myday Contact Lens, Clariti Contact Lens, Misight Contact Lens |
| Johnson & Johnson Surgical Vision, INC. | $1,413.01 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $363.39 | 2024-2025 | Xdemvy |
| Abbvie INC. | $325.08 | 2022-2025 | |
| Optos, INC. | $318.24 | 2019-2022 | |
| Alcon Vision LLC | $211.15 | 2021-2025 | Tryptyr, Precision7 |
| Allergan, INC. | $200.63 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $196.15 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $194.90 | 2019-2021 | |
| Visionary Optics LLC | $147.83 | 2024 | |
| Oyster Point Pharma, INC. | $142.59 | 2022-2024 | Tyrvaya, Ryzumvi |
| Sun Pharmaceutical Industries INC. | $132.98 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $121.99 | 2025 | |
| Maculogix, INC. | $109.43 | 2021 | |
| Bausch & Lomb Americas INC. | $97.61 | 2022-2025 | Vyzulta, Infuse |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $76.45 | 2024-2025 | Vevye |
| Biotissue Holdings INC. | $64.20 | 2022 | |
| Dompe US, INC. | $42.67 | 2020-2023 | Oxervate |
| Shire North American Group INC | $42.47 | 2019 | |
| Eyevance Pharmaceuticals LLC | $41.13 | 2019-2022 | |
| Carl Zeiss Meditec USA, INC. | $40.91 | 2021 | |
| Ivantis, INC | $15.58 | 2021 | |
| Novartis Pharmaceuticals Corporation | $14.53 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Oliver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.